( Dial-in information: North America (t...)Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis,Health

Dial-in information: North America (toll free): 1-866-713-8310 International: 1-617-597-5308 Enter passcode: 82004406

The call will be available for replay until Wednesday, July 5, 2007 by calling 1-888-286-8010 (North America) or 1-617-801-6888 (International) and entering the pass code 55009709. A live webcast will also be available to all interested parties on Aspreva's website: http://www.aspreva.com. Please click on the "Webcasts and Events" link under the Investors section of Aspreva's website. A replay of the webcast will be available until the Company's second quarter 2007 conference call.

About CellCept

CellCept (mycophenolate mofetil, MMF) is an immunosuppressant or anti-rejection drug approved for use in combination with other immunosuppressive drugs (cyclosporine and corticosteroids) for the prevention of rejection in patients receiving kidney, heart and liver transplants. There are no adequate and well-controlled studies in pregnant women. As CellCept has been shown to have teratogenic effects in animals at subclinical doses on a body surface area basis, it may cause fetal harm when administered to a pregnant woman. CellCept should not be used in pregnant women unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within one week prior to beginning therapy even where there has been a history of infertility, unless due to hysterectomy. Women of childbearing potential must use effective contraception before beginning CellCept therapy, during therapy and for six weeks following discontinuation of therapy. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method. If pregnancy occurs during treatment, the physician and patient should discuss the desirability of continuing the
'"/>